Podcast Synopsis of Updates to the European Renal Best Practice and UK Kidney Association Guidelines for Treatment of Anaemia in Chronic Kidney Disease.

Mario Cozzolino, Sokratis Stoumpos, Sunil Bhandari

Abstract readEditorialWebcast

In one paragraph

Article in Advances in therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mario CozzolinoRenal Division, ASST Santi Paolo E Carlo, Department of Health Sciences, University of Milan, Milan, Italy. mario.cozzolino@unimi.it.ORCID http://orcid.org/0000-0002-8494-6252

Sokratis StoumposRenal and Transplant Unit, Queen Elizabeth University Hospital, Glasgow, UK.

Sunil BhandariHull University Teaching Hospitals National Health Service Trust, Hull, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypoxia-inducible factor prolyl hydroxylase inhibitors (HIF-PHIs) were developed as an alternative to erythropoiesis-stimulating agents (ESAs) for the treatment of anaemia of chronic kidney disease (CKD). In 2024, the European Renal Best Practice Board (ERBP) of the European Renal Association published a clinical practice document for the use of HIF-PHIs; in 2025, the UK Kidney Association (UKKA) updated its treatment guidelines for anaemia of CKD, including HIF-PHIs as a recommended additional therapy. This podcast provides an overview of HIF-PHIs compared to ESAs, followed by a summary of general recommendations for the treatment of anaemia of CKD, with reference to both ERBP and UKKA guidelines. Considerations for prescribing ESAs and HIF-PHIs to specific patient groups, including those with inflammation, a history of cancer or cardiovascular events, kidney transplant recipients, and hospitalised patients, are then discussed. Podcast Audio (MP4 169314 KB).

Indexed as

AnemiaHematinicsHypoxia-Inducible Factor-Proline DioxygenasesProlyl-Hydroxylase InhibitorsRenal Insufficiency, ChronicEuropeHumansKidney TransplantationPractice Guidelines as TopicUnited KingdomHematinicsHypoxia-Inducible Factor-Proline DioxygenasesProlyl-Hydroxylase InhibitorsAnaemiaChronic kidney diseaseErythropoiesis-stimulating agentsEuropean Renal Best PracticeHypoxia-inducible factor prolyl hydroxylase enzyme inhibitorsUK Kidney Association

Identifiers

PMID40986184

DOI10.1007/s12325-025-03366-6

PMCPMC12579645

What OpenQuestion holds

Textmetadata

LicenceCC BY-NC

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.